Literature DB >> 6707947

Kinetics of drug action in disease states. I. Effect of infusion rate on phenobarbital concentrations in serum, brain and cerebrospinal fluid of normal rats at onset of loss of righting reflex.

M Danhof, G Levy.   

Abstract

The purpose of this investigation was to develop a method to determine the effect of various diseases on the concentration-pharmacologic activity relationship of phenobarbital (PB) in a manner that excludes or accounts for pharmacokinetic variables affecting drug disposition. Adult female rats (congruent to 180 g) received an i.v. infusion of PB at one of five different rates (0.412-4.12 mg/min) until the animals lost their righting reflex (after 8.0 +/- 0.4 to 62 +/- 10 min of infusion). The total dose, the serum concentration (both total and unbound drug) and the brain concentration of PB at onset of loss of righting reflex (LRR) increased with increasing infusion rate. The PB concentration in cerebrospinal fluid at onset of LRR (mean +/- S.D.: 108 +/- 19 micrograms/ml, n = 29) was not affected by the infusion rate. Concomitant infusion of PB and its p-hydroxy metabolite had no apparent effect on the concentrations of PB at onset of LRR even though the serum concentration of p-hydroxy PB was higher than upon infusion of PB only. The results of this investigation indicate that cerebrospinal fluid, unlike some regions of the brain, equilibrates very rapidly with the biophase of the receptors for PB-induced LRR. Determination of PB concentrations in the cerebrospinal fluid at the onset (rather than offset) of action facilitates assessment of the effect of diseases on the PB concentration-pharmacologic activity relationship by avoiding development of acute tolerance and excluding or minimizing effects due to disease-associated pharmacokinetic variables such as altered plasma protein binding and body distribution of the drug.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6707947

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  32 in total

1.  Antagonistic interaction between the convulsant activities of pefloxacin and its main metabolite norfloxacin in rats.

Authors:  A Delon; L M Levasseur; M Giraudon; S Bouquet; W Couet
Journal:  Pharm Res       Date:  1999-12       Impact factor: 4.200

2.  Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of imipenem in healthy rats.

Authors:  A Dupuis; W Couet; J Paquereau; S Debarre; A Portron; C Jamois; S Bouquet
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Age and the pharmacokinetic-pharmacodynamic relationship of phenobarbital in rats: "pseudo"-longitudinal vs cross-sectional study design.

Authors:  A M Stijnen; M Danhof; C F van Bezooijen
Journal:  Pharm Res       Date:  1992-11       Impact factor: 4.200

4.  Perspectives on the history and scientific contributions of Gerhard Levy.

Authors:  Ho-Leung Fung; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-24       Impact factor: 2.745

5.  Estimation of amobarbital plasma-effect site equilibration kinetics. Relevance of polyexponential conductance functions.

Authors:  J W Mandema; P Veng-Pedersen; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1991-12

6.  Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of heptabarbital using aperiodic EEG analysis.

Authors:  J W Mandema; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1990-10

7.  The unit impulse response procedure for the pharmacokinetic evaluation of drug entry into the central nervous system.

Authors:  J B van Bree; A V Baljet; A van Geyt; A G de Boer; M Danhof; D D Breimer
Journal:  J Pharmacokinet Biopharm       Date:  1989-08

8.  Effect of renal or hepatic dysfunction on neurotoxic convulsion induced by ranitidine in mice.

Authors:  M Shimokawa; K Yamamoto; J Kawakami; Y Sawada; T Iga
Journal:  Pharm Res       Date:  1994-11       Impact factor: 4.200

9.  Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: milacemide.

Authors:  J Semba; G Curzon; P N Patsalos
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

10.  Pharmacodynamics of zoxazolamine and chlorzoxazone in rats.

Authors:  M Yasuhara; G Levy
Journal:  Pharm Res       Date:  1988-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.